CPS1 emerges as a dual-functional candidate in lung cancer patients, serving both as a potential diagnostic and prognostic biomarker [29,40,41,42] and a radiosensitizing therapeutic target to optimize radiotherapy efficacy through its novel role in metabolic regulation of DNA damage response pathways. Here, CPS1 is linked to lung carcinoma.